Tiotropium bromide is a selective antagonist of muscarinic receptors, mediating mainly bronchoconstriction, and has a relatively long duration of action, with a long half-life allowing for only one daily application, thus allowing for a more convenient and longer lasting bronchodilatory effect than the 3-4 daily doses of ipratropium bromide. The bronchoconstrictive effect of tiotropium bromide on choline, with prolonged protective effect, will improve the control of interlobular bronchoconstriction, when choline plays a more important role, therefore tiotropium bromide is a better anticholinergic drug, mainly used in the maintenance treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, maintenance treatment of concomitant dyspnea and prevention of acute attacks, tiotropium bromide than ipratropium bromide It is more effective than ipratropium bromide in improving lung function in patients.